Imaging transforming growth factor-Β signaling dynamics and therapeutic response in breast cancer bone metastasis

Nature Medicine

Volumn 15, Issue 8, 2009, Pages 960-966

  Korpal, Manav ^a   Yan, Jun ^a   Lu, Xin ^a   Xu, Shuwa ^a   Lerit, Dorothy A ^a   Kang, Yibin ^a,b  

^a PRINCETON UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DOXYCYCLINE; EMD 616481; EMD 616482; LUCIFERASE; LY 2109761; PAMIDRONIC ACID; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CONTROLLED STUDY; DYNAMICS; HUMAN; HUMAN CELL; IMAGING; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VALIDATION STUDIES AS TOPIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68349160814     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1943     Document Type: Article

References (35)

1. Yingling, J.M., Blanchard, K.L. & Sawyer, J.S. Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011-1022 (2004).
2. Bierie, B. & Moses, H.L. Tumour microenvironment: TGF-β: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520 (2006).
3. Dumont, N. & Arteaga, C.L. Targeting the TGF-β signaling network in human neoplasia. Cancer Cell 3, 531-536 (2003).
4. Massagué, J. TGF-β in cancer. Cell 134, 215-230 (2008).
5. Yin, J.J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
6. Padua, D. et al. TGF-β primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (2008).
7. Kang, Y. et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 102, 13909-13914 (2005).
8. Muraoka-Cook, R.S. et al. Activated type I TGF-β receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25, 3408-3423 (2006).
9. Mundy, G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002).
10. Roodman, G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664 (2004).
11. Guise, T.A. et al. Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer 5 Suppl, S46-S53 (2005).
12. PfeiIschifter, J. & Mundy, G.R. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA 84, 2024-2028 (1987).
13. Dallas, S.L., Rosser, J.L., Mundy, G.R. & Bonewald, L.F. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix. J. Biol. Chem. 277, 21352-21360 (2002).
14. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
15. Minn, A.J. et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44-55 (2005).
16. Zawel, L. et al. Human SMAD3 and SMAD4 are sequence-specific transcription activators. Mol. Cell 1, 611-617 (1998).
17. Lin, A.H., Luo, J., Mondshein, L.H., ten Dijke, P., Vivien, D., Contag, C.H. & Wyss-Coray, T. Global analysis of Smad2/3-dependent TGF-β signaling in living mice reveals prominent tissue-specific responses to injury. J. Immunol. 175, 547-554 (2005).
18. Melisi, D. et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840 (2008).
19. Li, H.Y. et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent. J. Med. Chem. 51, 2302-2306 (2008).
20. Russell, R.G. et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. NY Acad. Sci. 1117, 209-257 (2007).
21. Gross, S. & Piwnica-Worms, D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell 7, 5-15 (2005).
22. Gelovani Tjuvajev, J. & Blasberg, R.G. in vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 3, 327-332 (2003).
23. Deroose, C.M. et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT and bioluminescence imaging. J. Nucl. Med. 48, 295-303 (2007).
24. Hoffman, R.M. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin. Exp. Metastasis 26, 345-355 (2009).
25. Fritz, V. et al. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model. Bone 40, 1032-1040 (2007).
26. Body, J.J.D.I., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., Tripathy, D. & Bergstrom, B. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br. J. Cancer 90, 1133-1137 (2004).
27. Tripathy, D., Lichinitzer, M., Lazarev, A., MacLachlan, S.A., Apffelstaedt, J., Budde, M., Bergstrom, B. & MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann. Oncol. 15, 743-750 (2004).
28. El-Abdaimi, K. et al. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone. Int. J. Oncol. 22, 883-890 (2003).
29. van der Pluijm, G. et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 65, 7682-7690 (2005).
30. Coleman, R.E., Purohit, O.P., Vinholes, J.J. & Zekri, J. High dose pamidronate. Cancer 80, 1686-1690 (1997).
31. Coleman, R. On the horizon: can bisphosphonates prevent bone metastases? Breast 16 Suppl 3, S21-S27 (2007).
32. Diel, I.J. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339, 357-363 (1998).
33. Ray, P., De, A., Min, J.J., Tsien, R.Y. & Gambhir, S.S. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res. 64, 1323-1330 (2004).
34. Voorhoeve, P.M. & Agami, R. The tumor-suppressive functions of the human INK4A locus. CancerCell 4, 311-319 (2003).
35. Reynisdóttir, I., Polyak, K., lavarone, A. & Massagué, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9, 1831-1845 (1995).